证券代码：600511 证券简称：国药股份 公告编号：临 2025-012 国药集团药业股份有限公司 第八届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 1 全体委员一致同意提交董事会审议。 内容详见上海证券交易所网站 www.sse.com.cn 同日披露的 国药股份 2025 年第一季度报告。 （二）以 8 票同意、0 票反对和 0 票弃权的结果审议通过《国 药股份 2024 年度环境、社会及治理（ESG）报告》。 一、董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第二十四次会议通知及资料于 2025 年 4 月 14 日以书面、电子邮件等形式发出，会议于 2025 年 4 月 24 日 以现场和通讯方式在北京召开。本次会议应到董事八名，实到董 事八名，其中四名独立董事参加了会议，公司党委书记、董事蒋 昕女士（代董事长）主持本次会议，监事和部分高管列席会议， 符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议并通过了 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于国药集团药业股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]A0133 号 致：国药集团药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《国药集团药业 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 12,713,002,292.38, representing a 4.87% increase compared to CNY 12,122,142,562.33 in the same period last year[4]. - The net profit attributable to shareholders was CNY 459,015,386.52, showing a slight decrease of 0.10% from CNY 459,454,518.02 year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 446,230,701.31, down 2.57% from CNY 457,982,149.39 in the previous year[4]. - The basic earnings per share for the period was CNY 0.6084, a decrease of 0.08% from CNY 0.6089 in the same period last year[4]. - The diluted earnings per share also stood at CNY 0.6084, reflecting the same decrease of 0.08% year-on-year[4]. - Operating profit for Q1 2025 was ¥600.66 million, slightly down from ¥613.80 million in Q1 2024[17]. - The company reported an investment income of ¥116.03 million in Q1 2025, up from ¥104.98 million in Q1 2024[16]. - The company experienced a decrease in comprehensive income, totaling ¥484.98 million in Q1 2025, compared to ¥489.27 million in Q1 2024[18]. - The net profit for the first quarter of 2025 was CNY 337.04 million, up by 6.8% from CNY 315.67 million in the same period last year[26]. Cash Flow - The net cash flow from operating activities was negative at CNY -1,893,175,718.90, compared to CNY -1,719,799,376.67 in the same period last year[4]. - Cash flow from operating activities showed a net outflow of ¥1.89 billion in Q1 2025, compared to a net outflow of ¥1.72 billion in Q1 2024[20]. - The net cash flow from operating activities for Q1 2025 was -182,256,312.16, an improvement from -301,387,089.18 in Q1 2024, indicating a reduction in cash outflow[29]. - Total cash inflow from operating activities in Q1 2025 was 5,789,069,778.39, compared to 5,539,406,936.00 in Q1 2024, reflecting a year-over-year increase of approximately 4.5%[29]. - Cash outflow from operating activities in Q1 2025 was 5,971,326,090.55, up from 5,840,794,025.18 in Q1 2024, representing an increase of about 2.2%[29]. - The cash inflow from operating activities was primarily driven by sales revenue of 5,778,772,698.76 in Q1 2025, compared to 5,414,211,225.58 in Q1 2024, marking an increase of approximately 6.7%[29]. - The company reported a cash outflow of 234,445,715.29 for taxes paid in Q1 2025, compared to 194,489,069.09 in Q1 2024, which is an increase of about 20.5%[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 35,096,471,073.69, a 0.48% increase from CNY 34,928,279,243.62 at the end of the previous year[5]. - The total assets of the company as of March 31, 2025, amounted to CNY 35,096,471,073.69, an increase from CNY 34,928,279,243.62 at the end of 2024[12]. - The company's current assets totaled CNY 30,442,472,468.14, slightly up from CNY 30,356,823,125.08 in the previous period[12]. - The total liabilities decreased to CNY 15,636,451,007.66 from CNY 15,953,235,952.60[13]. - The company's total current liabilities decreased to CNY 10.66 billion as of March 31, 2025, down from CNY 12.22 billion at the end of 2024, a reduction of approximately 12.8%[23]. - The company's cash and cash equivalents were reported at CNY 8,847,209,696.57, down from CNY 10,885,676,736.04[11]. - Cash and cash equivalents at the end of Q1 2025 were ¥6.27 billion, down from ¥9.19 billion at the end of Q1 2024[20]. - The cash and cash equivalents decreased to CNY 8.22 billion from CNY 10.30 billion, a decline of about 20.2%[22]. - The ending cash and cash equivalents balance for Q1 2025 was 5,670,552,754.10, down from 8,279,843,440.17 in Q1 2024, reflecting a decrease of about 31%[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,500[9]. - The equity attributable to shareholders increased by 2.68% to CNY 17,587,021,750.39 from CNY 17,128,090,785.52 at the end of the previous year[5]. - The company's equity attributable to shareholders increased to CNY 17,587,021,750.39 from CNY 17,128,090,785.52[14]. - The total equity increased to CNY 14.16 billion as of March 31, 2025, compared to CNY 13.83 billion at the end of 2024, reflecting a growth of approximately 2.4%[24]. Inventory and Receivables - Accounts receivable rose to CNY 14,262,746,580.18 from CNY 12,330,407,168.68, indicating a growth of approximately 15.7%[11]. - Inventory levels increased to CNY 5,042,936,676.44 from CNY 4,955,697,408.61, reflecting a growth of about 1.8%[12]. - The company's inventory remained stable at CNY 2.51 billion, showing a slight increase of 0.03% compared to CNY 2.51 billion at the end of 2024[22]. - The total non-current assets amounted to CNY 4,653,998,605.55, up from CNY 4,571,456,118.54[12]. Financial Expenses and Income - The company's financial expenses improved, with a net financial income of CNY 3.39 million in Q1 2025, compared to a loss of CNY 20.26 million in Q1 2024[25]. - The company reported an increase in investment income to CNY 113.86 million in Q1 2025, up from CNY 106.55 million in the same quarter of the previous year[25].

国药集团药业股份有限公司 China National Medicines Corporation Ltd. 2024年度 环境、社会和公司治理报告 Environmental, Social and Governance Report 公司地址 ：北京市东城区永定门西滨河路8号院7楼西塔6-9层 邮政编码 ：100077 联系电话 ：010-67271828 电子邮箱 ：gygfzqb@sinopharm.com 公司网站 ：www.cncm.com.cn 股票简称：国药股份 股票代码：600511 上海证券交易所发行上市 股票简称：国药股份 股票代码：600511 上海证券交易所发行上市 01 03 05 07 09 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 02 04 06 08 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 ...

国药股份（600511）公告，2025年第一季度营收为127.13亿元，同比增长4.87%；净利润为4.59亿元， 同比下降0.10%。 ...

Core Viewpoint - The company emphasizes balancing retained earnings for acquisitions and shareholder returns, with a focus on enhancing market confidence through share buybacks and increased dividends [2][3]. Financial Performance - In 2024, the company reported revenue of 1.659 billion RMB, a decrease of 4.75% year-on-year, while net profit reached 533 million RMB, an increase of 1.70% [12]. - Total assets grew to 5.575 billion RMB, up 7.71% from the previous year, and equity attributable to shareholders increased by 11.11% to 4.139 billion RMB [12]. Strategic Partnerships - The collaboration with China National Pharmaceutical Group (Sinopharm) has led to significant growth in procurement contracts, customer numbers, and product varieties [3][5]. - The company is leveraging Sinopharm's resources to enhance its market presence and operational synergy [3][5]. Market Challenges and Strategies - The IVD industry faces challenges due to intensified competition and price reductions from centralized procurement, with reagent prices dropping by 50-80% [4][11]. - The company plans to maintain its market position through marketing-driven strategies, refined management, and diversification [4][11]. Innovation and R&D - The company is focusing on expanding its product lines across various fields, including biochemistry, pathology, and immunology, while increasing R&D investments [9][10]. - AI technology is being integrated into pathology diagnostics, with ongoing collaborations with leading universities to enhance diagnostic efficiency and accuracy [6][19]. Export and International Market - The company's export business has seen a 36.57% increase in 2024, with a strong competitive edge in the immunohistochemistry sector [16][13]. - The company has established a research center with Xiamen University to develop AI-assisted diagnostic systems, indicating a commitment to innovation in the international market [19].

仓储物流毛利率下滑较多，控费良好。2024 年公司实现毛利率7.1%，同比-0.9 pct。 其中商品销售、产品销售、仓储物流毛利率分别为6.6%、34.8%、17.8%，同比-0.5/+1.7/-8.2 pct。销 售、管理、财务费用率分别为1.6%、0.9%、-0.1%，同比-0.3pct、基本持平、+0.1 pct（2023 年同期 为-0.3%）。经营性现金流同比下滑39.2%至16.6 亿元，主要是由于部分客户回款周期有所延长，带量采 购品种付款压力加大，以及资金筹措结构调整所致。 事件：国药股份公布2024 年全年业绩。2024 年公司实现收入506 亿元，同比+1.8%，实现归母净利润为 20 亿元，同比-6.8%。24Q4 单季度公司实现收入125.7 亿元，同比-4.5%，实现归母净利润5.2 亿元，同 比-24.1%。 受部分子公司利润大幅下滑影响，拖累整体利润。商品销售实现收入529 亿元，同比+3.6%；产品销售 实现收入4.7 亿元，同比-56.4%；仓储物流实现收入3.9 亿元，同比+8.4%。商品销售板块中，母公司实 现收入218.1 亿元，同比+3.2%，净利润15.5 亿元， ...

Core Viewpoint - Xinhua Insurance has increased its stake in Beijing Enterprises Holdings Limited, acquiring an additional 150,000 shares, bringing its total ownership to approximately 5% of the company's total issued shares [1][2]. Group 1: Investment Activity - Xinhua Insurance acquired 150,000 shares of Beijing Enterprises on March 26, 2025, through a secondary market auction, which represents 0.01% of the total issued shares [1][2]. - Prior to this acquisition, Xinhua Insurance held 6,278,850 shares, which accounted for 4.99% of Beijing Enterprises' total issued shares [2]. - After the transaction, the total shares held by Xinhua Insurance increased to 62,938,500, representing 5% of the total issued shares of Beijing Enterprises [2]. Group 2: Financial Performance of Beijing Enterprises - In 2024, Beijing Enterprises reported a revenue of 84.064 billion yuan, reflecting a year-on-year growth of 2.13% [1]. - The net profit attributable to the parent company for 2024 was 5.123 billion yuan, which is a decline of 6.82% compared to the previous year [1]. - The basic earnings per share for Beijing Enterprises stood at 4.07 yuan [1]. Group 3: Strategic Rationale - Xinhua Insurance plans to categorize its investment in Beijing Enterprises as part of its equity investment management strategy [3]. - The company has been actively increasing its stakes in various listed companies since 2024, including Shanghai Pharmaceuticals and GuoYao Group, indicating a strategic shift towards equity investments [3]. - The Vice President of Xinhua Insurance stated that the company's investment activities are aimed at achieving long-term stable returns while adapting to current market conditions [3]. Group 4: Industry Trends - Since 2024, multiple insurance companies have been actively increasing their stakes in various sectors, including banking and utilities [3][4]. - For instance, Ping An Life has triggered multiple stake increases in banks such as China Merchants Bank and Postal Savings Bank [3]. - Longcheng Life has also shown a preference for infrastructure-related stocks, increasing its holdings in companies like Datang Renewable and China Water Affairs [4]. Group 5: Market Conditions - According to GuoXin Securities, insurance companies are facing pressure on their asset side due to declining long-term interest rates and ongoing volatility in the equity market [5]. - The report suggests that insurance companies are likely to continue increasing their allocation to high-dividend and high-capital appreciation potential stocks to meet long-term and stable demand [5]. - The strategy of acquiring stakes in listed companies is seen as a way to smooth accounting profits and reduce volatility in investment returns [5].

Core Viewpoint - Xinhua Insurance has increased its stake in Beijing Holdings to 5% through secondary market transactions, marking its second stake increase this year, following its acquisition of Hangzhou Bank in January [1][2][5]. Group 1: Company Actions - Xinhua Insurance announced the acquisition of an additional 150,000 shares of Beijing Holdings, raising its total holdings to 62,938,500 shares, which represents 5% of the company's total equity [3][4]. - The company has been active in the capital market, having previously increased its stakes in several companies, including China National Pharmaceutical Group, Shanghai Pharmaceuticals, and Haitong Securities [5][6]. Group 2: Financial Metrics - As of March 26, Xinhua Insurance's equity assets amounted to 317.47 billion yuan, accounting for 21.13% of its total assets, which were reported at 1,692.297 billion yuan with a net asset value of 96.24 billion yuan [4][6]. - The solvency ratio of Xinhua Insurance stands at 217.55%, indicating a strong capital position [4]. Group 3: Market Trends - The insurance sector has seen increased activity in the capital markets, with several major insurance companies, including China Life and Ping An Life, participating in stake increases across 13 listed companies this year [6]. - The banking sector has emerged as a favored investment area for insurance capital, followed by public utilities and energy companies, reflecting a strategic focus on stable and high-quality companies [6].

Core Viewpoint - Xinhua Insurance aims to serve as a key player in supporting the real economy and maintaining financial stability, showcasing significant growth in revenue and profit in 2024 [1][4]. Financial Performance - In 2024, Xinhua Insurance achieved an operating income of 1325.55 billion yuan, representing a year-on-year increase of 85.27% [3][4]. - The net profit for 2024 reached 262.29 billion yuan, marking a 201.07% increase compared to the previous year, setting a historical record [3][4]. - Total assets as of the end of 2024 amounted to 1.69 trillion yuan, also a new high for the company [4]. Investment Strategy - As of December 31, 2024, Xinhua Insurance's investment scale was 1.63 trillion yuan, with a total investment return rate of 5.8% and a comprehensive investment return rate of 8.5% [2][5]. - The company supported the real economy with an investment scale of 1.09 trillion yuan and a balance of investments aligned with national strategies of approximately 483.3 billion yuan [2][8]. Business Development - Xinhua Insurance's life insurance business saw a premium income of 1705.11 billion yuan in 2024, a 2.8% increase year-on-year [4]. - The new business value for the year was 62.53 billion yuan, reflecting a significant growth of 106.8% [4]. - The company established a comprehensive framework to enhance its service to national strategies, including a three-tier management structure [7]. Shareholder Returns - In 2024, Xinhua Insurance initiated a mid-term dividend distribution, paying out 0.54 yuan per share, totaling 1.685 billion yuan [10]. - The company plans to distribute a year-end cash dividend of 1.99 yuan per share, amounting to 6.208 billion yuan, leading to a total proposed dividend of 78.93 billion yuan for the year, an increase of 197.6% from the previous year [11][10]. Future Outlook - The year 2025 is anticipated to be a pivotal year for the insurance industry, with significant growth potential as the "New National Ten Articles" are fully implemented [12]. - The chairman of Xinhua Insurance emphasized the importance of leveraging opportunities for high-quality development by integrating insurance, investment, and service strategies [12].